Transform II

TRANSFORM II is a multicenter, international, investigator-driven randomized clinical trial including centers from Europe, Asia, and South America and is comparing Magic Touch Sirolimus drug-coated balloon (DCB) to any everolimus-eluting stent in a broad spectrum of coronary artery disease (CAD) patients with native vessel disease diameters of 2–3.5 mm and LL up to 50 mm. Differently from all the other much smaller studies published so far, as the name implies, this study will transform the era of angioplasty by testing the non-inferiority in terms of the primary endpoint of target lesion failure (TLF) and superiority in terms of net adverse clinical events (NACE) of drug-coated balloons over the current standard technique, drug-eluting stents, at 1 year. Patients will be followed up clinically up to 5 years.